Recommended use: Take 1 capsule once a day with liquid
NVOs Phase III REDEFINE 1 Study Sub-Analysis Data in Detail Following the sub-analysis of Novo Nordisks REDEFINE 1 study after 68 weeks, assuming all people adhered to treatment, it was observed that cagrilintide monotherapy led to clinically meaningful weight loss, with an average body weight reduction of 11.8% (12.5 kg) compared to 2.3% (2.5 kg) with placebo
T.CooperJ
Gradually include foods like vegetables, fruits (with the skin), whole grains, and legumes to nourish your gut and promote fullness
Diagnosis, treatment decisions, and care plans should always be made in consultation with your physician or an appropriate MPN specialist who is familiar with your individual medical history.
Corcoran GB, Todd EL, Racz WJ, Hughes H, Smith CV, Mitchell JR